Translation in cardiovascular stents and occluders: From biostable to fully degradable

Huang, Yingying; Wong, Yuk Shan; Ng, Herr Cheun Anthony; Boey, Freddy Yin Chiang; Venkatraman, Subbu

doi:10.1002/btm2.10066

Cited by 15 publications

(8 citation statements)

References 54 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous absorbable devices have successfully passed preclinical and regulatory hurdles, to include a wide array of suture materials, internal fracture fixation pins, and dermal fillers (hyaluronic acid, hydroxyapatite, Poly-L-Lactic Acid (PLLA), collagen; FDA 2018), and in 2016, the first absorbable drug eluting stent scaffold was approved (Huang et al 2017; Waksman 2016).…”

Section: Conceptual Benefits and Rationale For Usementioning

confidence: 99%

Pathology of Bioabsorbable Implants in Preclinical Studies

Rousselle¹,

Ramot

Nyska

et al. 2019

Toxicol Pathol

View full text Add to dashboard Cite

Bioabsorbable implants can be advantageous for certain surgical tissue bioengineering applications and implant-assisted tissue repair. They offer the obvious benefits of nonpermanence and eventual restoration of the native tissue's biomechanical and immunological properties, while providing a structural scaffold for healing and a route for additional therapies (i.e., drug elution). They present unique developmental, imaging, and histopathological challenges in the conduct of preclinical animal studies and in interpretation of pathology data. The bioabsorption process is typically associated with a gradual decline (over months to years) in structural strength and integrity and may also be associated with cellular responses such as phagocytosis that may confound interpretation of efficacy and safety end points. Additionally, as these implants bioabsorb, they become increasingly difficult to isolate histologically and thus imaging modalities such as microCT become very valuable to determine the original location of the implants and to assess the remodeling response in tandem with histopathology. In this article, we will review different types of bioabsorbable implants and commonly used bioabsorbable materials; additionally, we will address some of the most common challenges and pitfalls confronting histologists and pathologists in collecting, handling, imaging, preparing tissues through histology, evaluating, and interpreting study data associated with bioabsorbable implants.

show abstract

Section: Conceptual Benefits and Rationale For Usementioning

confidence: 99%

Pathology of Bioabsorbable Implants in Preclinical Studies

Rousselle¹,

Ramot

Nyska

et al. 2019

Toxicol Pathol

View full text Add to dashboard Cite

show abstract

“…These polyesters degrade in aqueous solutions spontaneously by hydrolysis. The scaffolds are biocompatible, degradation rate is alterable, and they are easy to construct, so they hold the promise for becoming candidates for pediatric cardiac applications [ 95 ].…”

Section: Biomaterials Clinically Utilized In Congenital Cardiac Sumentioning

confidence: 99%

Biofabrication in Congenital Cardiac Surgery: A Plea from the Operating Theatre, Promise from Science

Király

Vijayavenkataraman

2021

Micromachines

View full text Add to dashboard Cite

Despite significant advances in numerous fields of biofabrication, clinical application of biomaterials combined with bioactive molecules and/or cells largely remains a promise in an individualized patient settings. Three-dimensional (3D) printing and bioprinting evolved as promising techniques used for tissue-engineering, so that several kinds of tissue can now be printed in layers or as defined structures for replacement and/or reconstruction in regenerative medicine and surgery. Besides technological, practical, ethical and legal challenges to solve, there is also a gap between the research labs and the patients’ bedside. Congenital and pediatric cardiac surgery mostly deal with reconstructive patient-scenarios when defects are closed, various segments of the heart are connected, valves are implanted. Currently available biomaterials lack the potential of growth and conduits, valves derange over time surrendering patients to reoperations. Availability of viable, growing biomaterials could cancel reoperations that could entail significant public health benefit and improved quality-of-life. Congenital cardiac surgery is uniquely suited for closing the gap in translational research, rapid application of new techniques, and collaboration between interdisciplinary teams. This article provides a succinct review of the state-of-the art clinical practice and biofabrication strategies used in congenital and pediatric cardiac surgery, and highlights the need and avenues for translational research and collaboration.

show abstract

“…On the currently available treatment options for atherosclerosis, statins, which are hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, are the primary pharmacological approach to lowering LDL cholesterol level in the serum, a primary risk factor in coronary artery disease. When prevention of atherosclerosis fails, interventional therapies such as balloon angioplasty and stenting are required, but they are invasive and restenosis risks are significant in up to 16% for drug eluting stenting and 30% for bare metallic stenting [4,5]. However, all of these treatment approaches unfortunately fail to address localized oxidative damage and inflammation governing atherosclerosis.…”

mentioning

confidence: 99%

Precision nanomedicine in atherosclerosis therapy: how far are we from reality?

Wong¹,

Czarny²,

Venkatraman³

2019

prnano

Self Cite

View full text Add to dashboard Cite

Atherosclerosis, characterized by build-up of lipids and chronic inflammation of the arterial wall, is the primary cause of cardiovascular disease and is a leading cause of death worldwide. Currently available therapies are inadequate and warrant the demand for improved technologies for more effective treatment. Although primarily the domain of antitumor therapy, recent advances have shown the considerable potential of nanomedicine to advance atherosclerosis treatment. This Review details the arsenal of nanocarriers and molecules available for selective targeting in atherosclerosis, and emphasize the challenges in atherosclerosis treatment.

show abstract

Translation in cardiovascular stents and occluders: From biostable to fully degradable

Cited by 15 publications

References 54 publications

Pathology of Bioabsorbable Implants in Preclinical Studies

Pathology of Bioabsorbable Implants in Preclinical Studies

Biofabrication in Congenital Cardiac Surgery: A Plea from the Operating Theatre, Promise from Science

Precision nanomedicine in atherosclerosis therapy: how far are we from reality?

Contact Info

Product

Resources

About